Jay Olson
Stock Analyst at Oppenheimer
(4.30)
# 465
Out of 4,479 analysts
181
Total ratings
50%
Success rate
16.24%
Average return
Main Sectors:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Perform | $12 | $4.54 | +164.32% | 6 | Jun 18, 2024 | |
| GLTO Galecto | Maintains: Outperform | $10 → $9 | $0.46 | +1,850.16% | 3 | Jun 10, 2024 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $18 | $7.59 | +137.15% | 5 | May 15, 2024 | |
| STRO Sutro Biopharma | Maintains: Outperform | $10 | $2.96 | +237.84% | 5 | May 15, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $102 → $95 | $53.12 | +78.86% | 6 | May 10, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 | $15.84 | +19.95% | 11 | May 6, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $200 → $216 | $137.49 | +57.10% | 11 | May 2, 2024 | |
| BIIB Biogen | Maintains: Outperform | $270 | $228.82 | +18.00% | 19 | Apr 29, 2024 | |
| INCY Incyte | Maintains: Outperform | $92 → $84 | $59.02 | +42.32% | 8 | Apr 24, 2024 | |
| SAGE Sage Therapeutics | Maintains: Perform | $25 → $17 | $10.82 | +57.12% | 7 | Apr 18, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $43 → $45 | $37.38 | +20.39% | 6 | Apr 12, 2024 | |
| SKYE Skye Bioscience | Initiates: Outperform | $25 | $7.56 | +230.69% | 1 | Apr 12, 2024 | |
| QTTB Q32 Bio | Initiates: Outperform | $50 | $18.05 | +177.01% | 1 | Apr 11, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $72 → $75 | $45.14 | +66.15% | 3 | Apr 9, 2024 | |
| VKTX Viking Therapeutics | Maintains: Outperform | $116 → $138 | $51.54 | +167.75% | 7 | Mar 27, 2024 | |
| CGTX Cognition Therapeutics | Maintains: Outperform | $9 | $1.82 | +394.51% | 4 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $320 → $375 | $271.67 | +38.04% | 7 | Mar 15, 2024 | |
| MRNS Marinus Pharmaceuticals | Maintains: Perform | $9 | $1.19 | +656.30% | 4 | Mar 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 | $22.78 | +251.19% | 4 | Mar 7, 2024 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.09 | +2,193.58% | 1 | Mar 5, 2024 | |
| ETNB 89bio | Maintains: Perform | n/a | $7.60 | - | 5 | Mar 5, 2024 | |
| PRTA Prothena Corporation | Maintains: Outperform | $98 → $80 | $20.39 | +292.35% | 8 | Feb 20, 2024 | |
| AMGN Amgen | Reiterates: Outperform | $350 | $310.77 | +12.62% | 16 | Feb 1, 2024 | |
| BIVI BioVie | Maintains: Outperform | $12 → $5 | $0.40 | +1,135.79% | 4 | Nov 30, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Perform | $25 → $21 | $13.45 | +56.13% | 7 | Nov 22, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $80 → $70 | $22.15 | +216.03% | 7 | Nov 13, 2023 | |
| EXEL Exelixis | Maintains: Outperform | $25 → $29 | $22.15 | +30.93% | 3 | Aug 22, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $70 → $68 | $21.74 | +212.79% | 3 | Jun 6, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Outperform | $55 | $19.81 | +177.64% | 2 | May 8, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Perform | $5 → $3 | $1.17 | +156.41% | 2 | Mar 6, 2023 | |
| RLMD Relmada Therapeutics | Downgrades: Perform | n/a | $2.99 | - | 2 | Oct 13, 2022 | |
| MDWD MediWound | Maintains: Outperform | n/a | $15.56 | - | 1 | Mar 20, 2018 | |
| TXMD TherapeuticsMD | Upgrades: Outperform | n/a | $1.66 | - | 2 | Jul 11, 2017 |
Editas Medicine
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $4.54
Upside: +164.32%
Galecto
Jun 10, 2024
Maintains: Outperform
Price Target: $10 → $9
Current: $0.46
Upside: +1,850.16%
Voyager Therapeutics
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $7.59
Upside: +137.15%
Sutro Biopharma
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $2.96
Upside: +237.84%
CRISPR Therapeutics AG
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $53.12
Upside: +78.86%
ACADIA Pharmaceuticals
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $15.84
Upside: +19.95%
Neurocrine Biosciences
May 2, 2024
Maintains: Outperform
Price Target: $200 → $216
Current: $137.49
Upside: +57.10%
Biogen
Apr 29, 2024
Maintains: Outperform
Price Target: $270
Current: $228.82
Upside: +18.00%
Incyte
Apr 24, 2024
Maintains: Outperform
Price Target: $92 → $84
Current: $59.02
Upside: +42.32%
Sage Therapeutics
Apr 18, 2024
Maintains: Perform
Price Target: $25 → $17
Current: $10.82
Upside: +57.12%
Revolution Medicines
Apr 12, 2024
Maintains: Outperform
Price Target: $43 → $45
Current: $37.38
Upside: +20.39%
Skye Bioscience
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $7.56
Upside: +230.69%
Q32 Bio
Apr 11, 2024
Initiates: Outperform
Price Target: $50
Current: $18.05
Upside: +177.01%
Ionis Pharmaceuticals
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $45.14
Upside: +66.15%
Viking Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $116 → $138
Current: $51.54
Upside: +167.75%
Cognition Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.82
Upside: +394.51%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $320 → $375
Current: $271.67
Upside: +38.04%
Marinus Pharmaceuticals
Mar 7, 2024
Maintains: Perform
Price Target: $9
Current: $1.19
Upside: +656.30%
Jasper Therapeutics
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $22.78
Upside: +251.19%
Immuneering
Mar 5, 2024
Reiterates: Outperform
Price Target: $25
Current: $1.09
Upside: +2,193.58%
89bio
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $7.60
Upside: -
Prothena Corporation
Feb 20, 2024
Maintains: Outperform
Price Target: $98 → $80
Current: $20.39
Upside: +292.35%
Amgen
Feb 1, 2024
Reiterates: Outperform
Price Target: $350
Current: $310.77
Upside: +12.62%
BioVie
Nov 30, 2023
Maintains: Outperform
Price Target: $12 → $5
Current: $0.40
Upside: +1,135.79%
Enanta Pharmaceuticals
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $13.45
Upside: +56.13%
Intellia Therapeutics
Nov 13, 2023
Maintains: Outperform
Price Target: $80 → $70
Current: $22.15
Upside: +216.03%
Exelixis
Aug 22, 2023
Maintains: Outperform
Price Target: $25 → $29
Current: $22.15
Upside: +30.93%
Denali Therapeutics
Jun 6, 2023
Maintains: Outperform
Price Target: $70 → $68
Current: $21.74
Upside: +212.79%
Bicycle Therapeutics
May 8, 2023
Reiterates: Outperform
Price Target: $55
Current: $19.81
Upside: +177.64%
Nektar Therapeutics
Mar 6, 2023
Maintains: Perform
Price Target: $5 → $3
Current: $1.17
Upside: +156.41%
Relmada Therapeutics
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.99
Upside: -
MediWound
Mar 20, 2018
Maintains: Outperform
Price Target: n/a
Current: $15.56
Upside: -
TherapeuticsMD
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.66
Upside: -